Allegro Raises $4.5M to Support Commercialization of Lung Cancer Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Allegro Diagnostics today announced it has closed a $4.5 million Series A extension financing.

Proceeds will be used to commercialize the company's BronchoGen test in 2012. The molecular testing platform uses gene expression of normal epithelial cells in the respiratory tract for the early detection of lung cancer.

Participants in the round included existing venture investors Kodiak Venture Partners and Catalyst Health Ventures.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.